Skip to main content
SpringerLink
Log in

Management of Hypertension in Patients with Chronic Kidney Disease

  • Pediatric Hypertension (B Falkner, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension is the leading factor in the global burden of disease. It is the predominant modifiable risk factor for stroke, heart disease, and kidney failure. Chronic kidney disease (CKD) is both a common cause and sequel of uncontrolled hypertension. The pathophysiology of CKD-associated hypertension is complex and multi-factorial. This paper reviews the key pathogenic mechanisms of CKD-associated hypertension, the importance of standardized blood pressure (BP) measurement in establishing the diagnosis and management plus the significance of ambulatory BP monitoring for assessment of diurnal BP variation commonly seen in CKD. The optimal BP target in CKD remains a matter of discussion despite recent clinical trials. Medical therapy can be difficult and challenging. In addition to lifestyle modification and dietary salt restriction, treatment may need to be individualized based on co-morbidities. Combination of antihypertensive drugs, including appropriate diuretic choice and dose, is of great significance in hypertension management in CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization. A global brief on hypertension: silent killer, global public health crisis. World health day 2013. Geneva: World Health Organization; 2013. p. 1–39.

    Google Scholar 

  2. Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS data brief, no 220. Hyattsville, MD: National Center for Health Statistics. 2015.

  3. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80:1258–70.

    Article  PubMed  Google Scholar 

  4. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55:441–51.

    Article  CAS  PubMed  Google Scholar 

  5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the Council for High Blood Pressure research. Hypertension. 2008;51:1403–19.

    Article  CAS  PubMed  Google Scholar 

  6. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61:2461–7.

    Article  PubMed  Google Scholar 

  7. Townsend RR, Taler SJ. Management of hypertension in chronic kidney disease. Nat Rev Nephrol. 2015;11:555–63.

    Article  PubMed  Google Scholar 

  8. Drawz PE, Abdalla M, Rahman M. Blood pressure measurement: clinic, home, ambulatory, and beyond. Am J Kidney Dis. 2012;60:449–62.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cohen DL, Huan Y, Townsend RR. Home blood pressure monitoring in CKD. Am J Kidney Dis. 2014;63:835–42.

    Article  PubMed  Google Scholar 

  10. Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-home study. Hypertension. 2010;55:1346–51.

    Article  CAS  PubMed  Google Scholar 

  11. Myers MG, Godwin M, Daves M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension. 2010;55:195–200.

    Article  CAS  PubMed  Google Scholar 

  12. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:1175–80.

    Article  CAS  PubMed  Google Scholar 

  13. Kanno A, Kikuya M, Asayama K, Satoh M, Inoue R, Hosaka M, et al. Night-time blood pressure is associated with the development of chronic kidney disease in a general population: the Ohasama study. J Hypertens. 2013;31:2410–7.

    Article  CAS  PubMed  Google Scholar 

  14. Ciobanu AO, Gherghinescu CL, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M, et al. The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes. Maedica (Buchar). 2013;8:129–36.

    Google Scholar 

  15. Mojón A, Ayala DE, Piñeiro L, Otero A, Crespo JJ, Moyá A, et al. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int. 2013;30:145–58.

    Article  PubMed  Google Scholar 

  16. Agarwal R. Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring. Curr Opin Nephrol Hypertens. 2006;15:309–13.

    Article  PubMed  Google Scholar 

  17. Agarwal R, Pappas MK, Sinha AD. Masked uncontrolled hypertension in CKD. J Am Soc Nephrol. 2016;27:924–32.

    Article  CAS  PubMed  Google Scholar 

  18. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25:2193–8.

    Article  CAS  PubMed  Google Scholar 

  19. Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension. 1982;4:190–7.

    Article  CAS  PubMed  Google Scholar 

  20. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012;82:388–400.

    Article  PubMed  Google Scholar 

  22. Hovater MB, Sanders PW. Effect of dietary salt on regulation of TGF-beta in the kidney. Semin Nephrol. 2012;32:269–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Luft FC, Weinberger MH. Review of salt restriction and the response to antihypertensive drugs: satellite symposium on calcium antagonists. Hypertension. 1988;11:I-229–32.

    Article  CAS  Google Scholar 

  24. Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2:385–95.

    Article  CAS  PubMed  Google Scholar 

  25. Boudville N, Ward S, Benaroia M, House AA. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens. 2005;18:1300–5.

    Article  CAS  PubMed  Google Scholar 

  26. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239–44.

    Article  PubMed  Google Scholar 

  27. Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev. 1976;56:1–56.

    CAS  PubMed  Google Scholar 

  28. Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013;22:1–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Svenningsen P, Friis UG, Versland JB, Buhl KB, Møller Frederiksen B, Andersen H, et al. Mechanisms of renal NaCl retention in proteinuric disease. Acta Physiol (Oxf). 2013;207:536–45.

    Article  CAS  Google Scholar 

  30. Buhl KB, Friis UG, Svenningsen P, Gulaveerasingam A, Ovesen P, Frederiksen-Møller B, et al. Urinary plasmin activates collecting duct ENaC current in preeclampsia. Hypertension. 2012;60:1346–51.

    Article  CAS  PubMed  Google Scholar 

  31. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625–33.

    Article  PubMed  Google Scholar 

  32. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. LeLorier J, Bombardier C, Burgess E, Moist L, Wright N, Cartier P, et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo‑oxygenase‑2 inhibitors in hypertension and kidney disease. Can J Cardiol. 2002;18:1301–8.

    CAS  PubMed  Google Scholar 

  34. Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension. 2000;36:461–5.

    Article  CAS  PubMed  Google Scholar 

  35. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A Meta-Analysis Ann Intern Med. 1994;121:289–300.

    Article  CAS  PubMed  Google Scholar 

  36. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens. 2001;14:971–5.

    Article  CAS  PubMed  Google Scholar 

  37. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62:218–25.

    Article  CAS  PubMed  Google Scholar 

  38. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35:1245–54.

    Article  PubMed  Google Scholar 

  39. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.

    Article  CAS  PubMed  Google Scholar 

  40. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

    Article  Google Scholar 

  41. McCullough PA, Steigerwalt S, Tolia K, Chen SC, Li S, Norris KC, et al. Cardiovascular disease in chronic kidney disease: data from the kidney early evaluation Program (KEEP). Curr Diab Rep. 2011;11:47–55.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al. CKD in the United States: kidney early evaluation program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51:S13–20.

    Article  CAS  PubMed  Google Scholar 

  43. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease study group. N Engl J Med. 1994;330:877–84.

    Article  CAS  PubMed  Google Scholar 

  44. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–31.

    Article  CAS  PubMed  Google Scholar 

  45. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN‑2): multicentre, randomised controlled trial. Lancet. 2005;365:939–46.

    Article  PubMed  Google Scholar 

  46. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

    Article  PubMed  Google Scholar 

  47. Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–8.

    Article  PubMed  Google Scholar 

  49. Drawz PE, Pajewski NM, Bates JT, et al. Effect of intensive versus standard clinic-based hypertension management on ambulatory blood pressure. Results from the SPRINT (systolic blood pressure intervention trial) ambulatory blood pressure study. Hypertension. 2017;69.

  50. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: implications for entry and achieved blood pressure values compared with other trials. Hypertension. 2016;67:808–12.

    Article  CAS  PubMed  Google Scholar 

  51. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337–414.

    Article  Google Scholar 

  52. National Institute for Health and Care Excellence. Chronic kidney disease http://www.nice.org.uk/guidance/cg182/evidence/cg182-chronic-kidney-disease.

  53. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30:485–501.

    Article  PubMed  Google Scholar 

  54. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.

    Article  CAS  PubMed  Google Scholar 

  55. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3–15.

    Article  CAS  PubMed  Google Scholar 

  56. American Diabetes Association. Standards of medical care in diabetes. Chapter 8 ‘cardiovascular disease and risk management’. Diabetes Care. 2016;39(Suppl. 1):S60–71.

    Google Scholar 

  57. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2016;32(5):569–88.

    Article  PubMed  Google Scholar 

  58. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension. 2005;45:1035–41.

    Article  CAS  PubMed  Google Scholar 

  59. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.

    Article  PubMed  Google Scholar 

  60. Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernandez-Sola J, Urbano-Marquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension. 1999;33:653–7.

    Article  CAS  PubMed  Google Scholar 

  61. Singer DR, Markandu ND, Sugden AL, Miller MA, MacGregor GA. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension. 1991;17:798–803.

    Article  CAS  PubMed  Google Scholar 

  62. Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2:385–95.

    Article  CAS  PubMed  Google Scholar 

  63. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. N Engl J Med. 1997;336:1117–24.

    Article  CAS  PubMed  Google Scholar 

  64. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906.

    Article  PubMed  Google Scholar 

  65. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829–40.

    Article  CAS  PubMed  Google Scholar 

  66. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the action in diabetes and vascular disease: Preterax and Diamicron controlled evaluation (ADVANCE) trial. Hypertension. 2014;63:259–64.

    Article  CAS  PubMed  Google Scholar 

  67. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014;15:527–47.

    Article  CAS  PubMed  Google Scholar 

  68. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15:605–21.

    Article  CAS  PubMed  Google Scholar 

  69. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–8.

    Article  CAS  PubMed  Google Scholar 

  70. Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C, Bilancio G. Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension. 2014;63:692–7.

    Article  CAS  PubMed  Google Scholar 

  71. Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11–21.

    Article  CAS  PubMed  Google Scholar 

  72. Izzo JL. Value of combined thiazide-loop diuretic therapy in chronic kidney disease: heart failure and reninangiotensin-aldosterone blockade. J Clin Hypertens. 2012;14:344.

    Article  Google Scholar 

  73. Anderson S, Brenner BM. Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am J Hypertens. 1988;1:380S–3S.

    Article  CAS  PubMed  Google Scholar 

  74. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282–7.

    Article  CAS  PubMed  Google Scholar 

  75. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.

    Article  Google Scholar 

  76. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.

    Article  CAS  PubMed  Google Scholar 

  77. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991–2002.

    Article  CAS  PubMed  Google Scholar 

  78. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.

    Article  CAS  PubMed  Google Scholar 

  79. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, et al. Renal outcomes in hypertensive black patients at high cardiovascular risk. Kidney Int. 2012;81:568–76.

    Article  CAS  PubMed  Google Scholar 

  80. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217–26.

    Article  CAS  PubMed  Google Scholar 

  81. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30.

    Article  CAS  PubMed  Google Scholar 

  83. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65:1372–407.

    Article  CAS  PubMed  Google Scholar 

  84. Hermida RC, Diana E, Ayala DE, Mojón A, Fernández JR. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22:2313–21.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011;58:1165–73.

    Article  CAS  PubMed  Google Scholar 

  86. Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens. 2006;8:174–80.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, Sidney Kimmel School of Medicine, Thomas Jefferson University, 833 Chestnut Street, Suite 700, Philadelphia, PA, 19107, USA

    Seyed Mehrdad Hamrahian

Authors
  1. Seyed Mehrdad Hamrahian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seyed Mehrdad Hamrahian.

Ethics declarations

Conflict of Interest

Dr. Hamrahian declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pediatric Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamrahian, S.M. Management of Hypertension in Patients with Chronic Kidney Disease. Curr Hypertens Rep 19, 43 (2017). https://doi.org/10.1007/s11906-017-0739-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-017-0739-9

Keywords

Search

Navigation